Over 12 million people in the United States died from all causes between the beginning of January 2020 and August 21, 2023. Over 1.1 million of those deaths were with confirmed or presumed COVID-19.

Vaccine rollout in the United States Finding a safe and effective COVID-19 vaccine was an urgent health priority since the very start of the pandemic. In the United States, the first two vaccines were authorized and recommended for use in December 2020. One has been developed by Massachusetts-based biotech company Moderna, and the number of Moderna COVID-19 vaccines administered in the U.S. was over 250 million. Moderna has also said that its vaccine is effective against the coronavirus variants first identified in the UK and South Africa.

Deaths counts for influenza, pneumonia, and COVID-19 reported to NCHS by week ending date, by state and HHS region, and age group.

Between January and August 2020, there has been approximately 48.2 thousand deaths in England and Wales with COVID-19 as an underlying cause. As illustrated in the table, the number of deaths as a result of COVID-19 are much higher than from either pneumonia or influenza. There has been over three times the number of deaths from COVID-19 than pneumonia and influenza so far in 2020. The overall number of confirmed COVID-19 cases in the UK can be found here. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

As of January 6, 2022, an average of 1,192 people per day have died from COVID-19 in the U.S. since the first case was confirmed in the country on January 20th the year before. On an average day, nearly 8,000 people die from all causes in the United States, based on data from 2019. Based on the latest information, roughly one in seven deaths each day were related to COVID-19 between January 2020 and January 2022. However, there were even days when more than every second death in the U.S. was connected to COVID-19. The daily death toll from the seasonal flu, using preliminary maximum estimates from the 2019-2020 influenza season, stood at an average of around 332 people. We have to keep in mind that a comparison of influenza and COVID-19 is somewhat difficult. COVID-19 cases and deaths are counted continuously since the begin of the pandemic, whereas flue counts are seasonal and often less accurate. Furthermore, during the last two years, COVID-19 more or less 'replaced' the flu, with COVID-19 absorbing potential flu cases. Many countries reported a very weak seasonal flu activity during the COVID-19 pandemic. But it has yet to be seen how the two infectious diseases will develop side by side during the winter season 2021/2022 and in the years to come.

Symptoms and self-isolation COVID-19 and influenza share similar symptoms – a cough, runny nose, and tiredness – and telling the difference between the two can be difficult. If you have minor symptoms, there is no need to seek urgent medical care, but it is recommended that you self-isolate, whereas rules vary from country to country. Additionally, rules depend on someone's vaccination status and infection history. However, if you think you have the disease, a diagnostic test can show if you have an active infection.

Scientists alert to coronavirus mutations The genetic material of the novel coronavirus is RNA, not DNA. Other notable human diseases caused by RNA viruses include SARS, Ebola, and influenza. A continual problem that vaccine developers encounter is that viruses can mutate, and a treatment developed against a certain virus type may not work on a mutated form. The seasonal flu vaccine, for example, is different each year because influenza viruses are frequently mutating, and it is critical that those genetic changes continue to be tracked.

Context

Dataset aims to facilitate a state by state comparison of potential risk factors that may heighten Covid 19 transmission rates or deaths. It includes state by state estimates of: covid 19 positives/deaths, flu/pneumonia deaths, major city population densities, available hospital resources, high risk health condition prevalance, population over 60, means of work transportation rates, housing characteristics (ie number of large apartment complexes/seniors living alone), and industry information.

Content

The Data Includes:

1) Covid 19 Outcome Stats:

Covid_Death : Covid Deaths by State

Covid_Positive : Covid Positive Tests by State

2) US Major City Population Density by State: CBSA_Major_City_max_weighted_density

3) KFF Estimates of Total Hospital Beds by State:

Kaiser_Total_Hospital_Beds

4) 2018 Season Flu and Pneumonia Death Stats:

FLUVIEW_TOTAL_PNEUMONIA_DEATHS_Season_2018

FLUVIEW_TOTAL_INFLUENZA_DEATHS_Season_2018

5)US Total Rates of Flu Hospitalization by Underlying Condition:

Fluview_US_FLU_Hospitalization_Rate_....

6) State by State BRFSS Prevalance Rates of Conditions Associated with Higher Flu Hospitalization Rates

BRFSS_Diabetes_Prevalance BRFSS_Asthma_Prevalance BRFSS_COPD_Prevalance
BRFSS_Obesity BMI Prevalance BRFSS_Other_Cancer_Prevalance BRFSS_Kidney_Disease_Prevalance BRFSS_Obesity BMI Prevalance BRFSS_2017_High_Cholestoral_Prevalance BRFSS_2017_High_Blood_Pressure_Prevalance Census_Population_Over_60

7)State by state breakdown of Means of Work Transpotation:

COMMUTE_Census_Worker_Public_Transportation_Rate

8) State by state breakdown of Housing Characteristics

9) State by State breakdown of Industry Information

Acknowledgements

Links to data sources:

https://worldpopulationreview.com/states/

https://covidtracking.com/data/

https://gis.cdc.gov/GRASP/Fluview/FluHospRates.html https://www.kff.org/health-costs/issue-brief/state-data-and-policy-actions-to-address-coronavirus/#stateleveldata

https://data.census.gov/cedsci/table?q=United%20States&tid=ACSDP1Y2018.DP05&hidePreview=true&vintage=2018&layer=VT_2018_040_00_PY_D1&cid=S0103_C01_001E

Census Tables: ACSST1Y2018.S1811 ACSST1Y2018.S0102 ACSST1Y2018.S2403 ACSST1Y2018.S2501 ACSST1Y2018.S2504

https://www.census.gov/library/visualizations/2012/dec/c2010sr-01-density.html

https://gis.cdc.gov/grasp/fluview/mortality.html

Inspiration

I hope to show the existence of correlations that warrant a deeper county by county analysis to identify areas of increased risk requiring increased resource allocation or increased attention to preventative measures.

As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had spread to almost every country in the world, and more than 6.86 million people had died after contracting the respiratory virus. Over 1.16 million of these deaths occurred in the United States.

Waves of infections Almost every country and territory worldwide have been affected by the COVID-19 disease. At the end of 2021 the virus was once again circulating at very high rates, even in countries with relatively high vaccination rates such as the United States and Germany. As rates of new infections increased, some countries in Europe, like Germany and Austria, tightened restrictions once again, specifically targeting those who were not yet vaccinated. However, by spring 2022, rates of new infections had decreased in many countries and restrictions were once again lifted.

What are the symptoms of the virus? It can take up to 14 days for symptoms of the illness to start being noticed. The most commonly reported symptoms are a fever and a dry cough, leading to shortness of breath. The early symptoms are similar to other common viruses such as the common cold and flu. These illnesses spread more during cold months, but there is no conclusive evidence to suggest that temperature impacts the spread of the SARS-CoV-2 virus. Medical advice should be sought if you are experiencing any of these symptoms.

The Chicago Department of Public Health (CDPH) receives weekly deidentified provisional death certificate data for all deaths that occur in Chicago, which can include both Chicago and non-Chicago residents from the Illinois Department of Public Health (IDPH) Illinois Vital Records System (IVRS). CDPH scans for keywords to identify deaths with COVID-19, influenza, or respiratory syncytial virus (RSV) listed as an immediate cause of death, contributing factor, or other significant condition. The percentage of all reported deaths that are attributed to COVID-19, influenza, or RSV is calculated as the number of deaths for each respective disease divided by the number of deaths from all causes, multiplied by 100. This dataset reflects death certificates that have been submitted to IVRS at the time of transmission to CDPH each week – data from previous weeks are not updated with any new submissions to IVRS. As such, estimates in this dataset may differ from those reported through other sources. This dataset can be used to understand trends in COVID-19, influenza, and RSV mortality in Chicago but does not reflect official death statistics. Source: Provisional deaths from the Illinois Department of Public Health Illinois Vital Records System.

Data is from the California Department of Public Health (CDPH) Respiratory Virus Weekly Report. The report is updated each Friday. Laboratory surveillance data: California laboratories report SARS-CoV-2 test results to CDPH through electronic laboratory reporting. Los Angeles County SARS-CoV-2 lab data has a 7-day reporting lag. Test positivity is calculated using SARS-CoV-2 lab tests that has a specimen collection date reported during a given week. Laboratory surveillance for influenza, respiratory syncytial virus (RSV), and other respiratory viruses (parainfluenza types 1-4, human metapneumovirus, non-SARS-CoV-2 coronaviruses, adenovirus, enterovirus/rhinovirus) involves the use of data from clinical sentinel laboratories (hospital, academic or private) located throughout California. Specimens for testing are collected from patients in healthcare settings and do not reflect all testing for influenza, respiratory syncytial virus, and other respiratory viruses in California. These laboratories report the number of laboratory-confirmed influenza, respiratory syncytial virus, and other respiratory virus detections and isolations, and the total number of specimens tested by virus type on a weekly basis. Test positivity for a given week is calculated by dividing the number of positive COVID-19, influenza, RSV, or other respiratory virus results by the total number of specimens tested for that virus. Weekly laboratory surveillance data are defined as Sunday through Saturday. Hospitalization data: Data on COVID-19 and influenza hospital admissions are from Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN) Hospitalization dataset. The requirement to report COVID-19 and influenza-associated hospitalizations was effective November 1, 2024. CDPH pulls NHSN data from the CDC on the Wednesday prior to the publication of the report. Results may differ depending on which day data are pulled. Admission rates are calculated using population estimates from the P-3: Complete State and County Projections Dataset provided by the State of California Department of Finance (https://dof.ca.gov/forecasting/demographics/projections/). Reported weekly admission rates for the entire season use the population estimates for the year the season started. For more information on NHSN data including the protocol and data collection information, see the CDC NHSN webpage (https://www.cdc.gov/nhsn/index.html). CDPH collaborates with Northern California Kaiser Permanente (NCKP) to monitor trends in RSV admissions. The percentage of RSV admissions is calculated by dividing the number of RSV-related admissions by the total number of admissions during the same period. Admissions for pregnancy, labor and delivery, birth, and outpatient procedures are not included in total number of admissions. These admissions serve as a proxy for RSV activity and do not necessarily represent laboratory confirmed hospitalizations for RSV infections; NCKP members are not representative of all Californians. Weekly hospitalization data are defined as Sunday through Saturday. Death certificate data: CDPH receives weekly year-to-date dynamic data on deaths occurring in California from the CDPH Center for Health Statistics and Informatics. These data are limited to deaths occurring among California residents and are analyzed to identify influenza, respiratory syncytial virus, and COVID-19-coded deaths. These deaths are not necessarily laboratory-confirmed and are an underestimate of all influenza, respiratory syncytial virus, and COVID-19-associated deaths in California. Weekly death data are defined as Sunday through Saturday. Wastewater data: This dataset represents statewide weekly SARS-CoV-2 wastewater summary values. SARS-CoV-2 wastewater concentrations from all sites in California are combined into a single, statewide, unit-less summary value for each week, using a method for data transformation and aggregation developed by the CDC National Wastewater Surveillance System (NWSS). Please see the CDC NWSS data methods page for a description of how these summary values are calculated. Weekly wastewater data are defined as Sunday through Saturday.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

BackgroundCOVID-19 and influenza can both lead to acute kidney injury (AKI) as a common complication. However, no meta-analysis has been conducted to directly compare the incidence of AKI between hospitalized patients with COVID-19 and influenza. The objective of our study aims to investigate the incidence and outcomes of AKI among hospitalized patients between these two groups.Materials and methodsA systematic search of PubMed, Embase, and Cochrane databases was conducted from December 2019 to August 2023 to identify studies examining AKI and clinical outcomes among hospitalized patients with COVID-19 and influenza. The primary outcome of interest was the incidence of AKI, while secondary outcomes included in-hospital mortality, recovery from AKI, hospital and ICU stay duration. The quality of evidence was evaluated using Cochrane and GRADE methods.ResultsTwelve retrospective cohort studies, involving 17,618 hospitalized patients with COVID-19 and influenza, were analyzed. COVID-19 patients showed higher AKI incidence (29.37% vs. 20.98%, OR: 1.67, 95% CI 1.56–1.80, p 

For the week ending August 29, 2025, weekly deaths in England and Wales were 985 below the number expected, compared with 855 below what was expected in the previous week. In late 2022 and through early 2023, excess deaths were elevated for a number of weeks, with the excess deaths figure for the week ending January 13, 2023, the highest since February 2021. In the middle of April 2020, at the height of the COVID-19 pandemic, there were almost 12,000 excess deaths a week recorded in England and Wales. It was not until two months later, in the week ending June 19, 2020, that the number of deaths began to be lower than the five-year average for the corresponding week. Most deaths since 1918 in 2020 In 2020, there were 689,629 deaths in the United Kingdom, making that year the deadliest since 1918, at the height of the Spanish influenza pandemic. As seen in the excess death figures, April 2020 was by far the worst month in terms of deaths during the pandemic. The weekly number of deaths for weeks 16 and 17 of that year were 22,351, and 21,997 respectively. Although the number of deaths fell to more usual levels for the rest of that year, a winter wave of the disease led to a high number of deaths in January 2021, with 18,676 deaths recorded in the fourth week of that year. For the whole of 2021, there were 667,479 deaths in the UK, 22,150 fewer than in 2020. Life expectancy in the UK goes into reverse In 2022, life expectancy at birth for women in the UK was 82.6 years, while for men it was 78.6 years. This was the lowest life expectancy in the country for ten years, and came after life expectancy improvements stalled throughout the 2010s, and then declined from 2020 onwards. There is also quite a significant regional difference in life expectancy in the UK. In the London borough of Kensington and Chelsea, for example, the life expectancy for men was 81.5 years, and 86.5 years for women. By contrast, in Blackpool, in North West England, male life expectancy was just 73.1 years, while for women, life expectancy was lowest in Glasgow, at 78 years.

PurposeTo analyse the association between the mortality during the summer 2022 and either high temperatures or the COVID-19 wave with data from the Catalan Health Care System (7.8 million people).MethodsWe performed a retrospective study using publicly available data of meteorological variables, influenza-like illness (ILI) cases (including COVID-19) and deaths. The study comprises the summer months of the years 2021 and 2022. To compare the curves of mortality, ILI and temperature we calculated the z-score of each series. We assessed the observed lag between curves using the cross-correlation function. Finally, we calculated the correlation between the z-scores using the Pearson correlation coefficient (R2).ResultsDuring the study period, 33,967 deaths were reported in Catalonia (16,416 in the summer of 2021 and 17,551 in the summer of 2022). In 2022, the observed lag and the correlation between the z-scores of temperature and all-cause deaths was 3 days and R2 = 0.86, while between ILI and all-cause deaths was 22 days and R2 = 0.21. This high correlation between temperature and deaths increased up to 0.91 when we excluded those deaths reported as COVID-19 deaths, while the correlation between ILI and non-COVID-19 deaths decreased to −0.19. No correlation was observed between non-COVID deaths and temperature or ILI cases in 2021.ConclusionOur study suggests that the main cause of the increase in deaths during summer 2022 in Catalonia was the high temperatures and its duration. The contribution of the COVID-19 seems to be limited.

Background: Although coinfection with influenza in COVID-19 patients has drawn considerable attention, it is still not completely understood whether simultaneously infected with these two viruses influences disease severity. We therefore aimed to estimate the impact of coinfected with SARS-CoV-2 and influenza on the disease outcomes compared with the single infection of SARS-CoV-2.Materials and Methods: We searched the PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure Database (CNKI) to identify relevant articles up to July 9, 2021. Studies that assessed the effect of SARS-CoV-2 and influenza coinfection on disease outcomes or those with sufficient data to calculate risk factors were included. Risk effects were pooled using fixed or random effects model.Results: We ultimately identified 12 studies with 9,498 patients to evaluate the risk effects of SARS-CoV-2 and influenza coinfection on disease severity. Results indicated that coinfection was not significantly associated with mortality (OR = 0.85, 95%CI: 0.51, 1.43; p = 0.55, I2 = 76.00%). However, mortality was found significantly decreased in the studies from China (OR = 0.51, 95%CI: 0.39, 0.68; I2 = 26.50%), while significantly increased outside China (OR = 1.56, 95%CI: 1.12, 2.19; I2 = 1.00%). Moreover, a lower risk for critical outcomes was detected among coinfection patients (OR = 0.64, 95%CI: 0.43, 0.97; p = 0.04, I2 = 0.00%). Additionally, coinfection patients presented different laboratory indexes compared with the single SARS-CoV-2 infection, including lymphocyte counts and APTT.Conclusion: Our study revealed that coinfection with SARS-CoV-2 and influenza had no effect on overall mortality. However, risk for critical outcomes was lower in coinfection patients and different associations were detected in the studies from different regions and specific laboratory indexes. Further studies on influenza strains and the order of infection were warranted. Systematic testing for influenza coinfection in COVID-19 patients and influenza vaccination should be recommended.

The burden of influenza in the United States can vary from year to year depending on which viruses are circulating, how many people receive an influenza vaccination, and how effective the vaccination is in that particular year. During the 2023-2024 flu season, around 28,000 people lost their lives to the disease. Although most people recover from influenza without needing medical care, the disease can be deadly among young children, the elderly, and those with weakened immune systems or chronic illnesses. Deaths due to influenza Even though most people recover from influenza without medical care, influenza and pneumonia can be deadly, especially for older people and those with certain preexisting conditions. Influenza is a common cause of pneumonia and although most cases of influenza do not develop into pneumonia, those that do are often more severe and more deadly. Deaths due to influenza are most common among the elderly, with a mortality rate of around 32 per 100,000 population during the 2023-2024 flu season. In comparison, the mortality rate for those aged 50 to 64 years was 9.1 per 100,000 population. Flu vaccinations The most effective way to prevent influenza is to receive an annual influenza vaccination. These vaccines have proven to be safe and are usually cheap and easily accessible. Nevertheless, every year a large share of the population in the United States still fails to get vaccinated against influenza. For example, in the 2022-2023 flu season, only 35 percent of those aged 18 to 49 years received a flu vaccination. Unsurprisingly, children and the elderly are the most likely to get vaccinated. It is estimated that during the 2022-2023 flu season, vaccinations prevented over 929 thousand influenza cases among children aged 6 months to 4 years.